News

The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.

Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk

Eight presentations, including late-breaking science, live cases, and a landmark symposium

Electrophysiologists from around the globe come together in San Diego to advance the field of EP and improve patient outcomes.

CathVision, a leader in advanced cardiac electrophysiology (EP) technology, is pleased to announce its participation and exhibition at the Heart Rhythm Society (HRS) 2025 Annual Scientific Sessions at the San Diego Convention Center in San...

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, will showcase its transformative vMap technology at Heart Rhythm 2025, taking place April 25–27 in San Diego.

Sky Labs, a health-tech startup based in South Korea, announced that its ring-shaped smart medical device, CART-I (Cardio Tracker), demonstrated higher sensitivity than the Apple Watch in detecting atrial fibrillation (AFib) in a recent...

Adagio Medical Holdings, Inc., announced that it has received Breakthrough Device designation from the U.S. Food and Drug Administration for its vCLASTM Cryoablation System for the treatment of drug-refractory, recurrent, sustained...

Camzyos is an FDA-approved cardiac myosin inhibitor for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.(1)